Experience with cryo-preserved cadaveric femoral vein allografts used for hemodialysis access  by Madden, R.L. et al.
ABSTRACTS
Gregory L. Moneta, MD, Abstracts Section Editor
Experience with cryo-preserved cadaveric femoral vein allografts used
for hemodialysis access
Madden RL, Lipkowitz GS, Browne BJ, et al. Ann Vasc Surg 2004;18:
453-8.
Conclusion: Cadaveric vein allografts, when used for hemodialysis,
have similar patency to polytetrafluoroethylene (PTFE) grafts and a lower
rate of infection but are more susceptible to aneurysm degeneration.
Summary: Patients without adequate vasculature for construction of
an autogenous arterial venous fistula had dialysis access performed with
either vein allografts or PTFE grafts. Graft choice was at the surgeon’s
discretion. Before January 2001, only cryo-preserved veins were used. After
2001, decelluarized, cryo-preserved synergraft veins and PTFE grafts were
also used. Data were analyzed for patient demographics and graft-associated
complications and patency. The cryo-preserved group had 48 patients, the
PTFE group had 100 patients, and the synergraft group had 42 patients.
Demographics were similar among the three groups.
Primary and secondary patencies were not significantly different at 1 or
2 years between the three groups. Complication rates did differ. Complica-
tions in PTFE versus cryo-preserved and synergraft groups were aneurysm
(2% vs 8%, P  .001), steal syndrome (12% vs 12%, P  NS), and infection
(10% vs 0%, P  .001). More patients with vein allografts lost access
secondary to multiple stenosis (P  .05) or aneurysm (P  .01); whereas
PTFE patients lost more access secondary to infection (P  .01) and
recurrent thrombosis (P  0.05).
Comment: There is no ideal dialysis access for chronic hemodialysis.
Even native access is troubled by failures of maturation. Problems with
infection and thrombosis of synthetic access are well known. The relative
resistance of cryo-preserved veins to infection is also well known, but perhaps
the susceptibility to multiple stenoses and development of aneurysms is less
appreciated. The authors did not tell us about the relative expense of the
cryo-preserved access versus prosthetic access. This also may be a consider-
ation when alternatives are chosen to a native arterial venous fistula for
hemodialysis.
Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke
Alexandrov AV, Molina CA, Grotta JC, et al. N Engl J Med 2004;351:
2170-8.
Conclusion: The use of a combination of continuous transcranial
Doppler (TCD) ultrasonography and tissue plasminogen activator (tPA) in
patients with acute ischemic stroke induces arterial recanalization with an
associated trend towards an increased rate of recovery from stroke compared
with placebo.
Summary: The authors sought to determine whether ultrasonography
could enhance the thrombolitic activity of t-PA in patients with acute
ischemic stroke. Patients with acute ischemic stroke caused by occlusion of
the middle cerebral artery were treated with intravenous t-PA within 3 hours
after onset of symptoms. Patients were then randomized to receive either
placebo (control) or continuous 2-MHz TCD ultrasonography. The pri-
mary endpoint was complete recanalization as assessed by TCD ultrasonog-
raphy or dramatic clinical recovery. Secondary endpoints were recovery at 24
hours, and death or favorable outcome at 3 months.
The study included 126 patients, with 63 randomized to placebo
and 63 randomized to receive continuous TCD ultrasonography. Symp-
tomatic intracranial hemorrhage occurred in three patients in the ultra-
sound group and three in the control group. Dramatic clinical recovery
within 2 hours or complete recanalization of the target artery occurred in
31 patients (49%) in ultrasound group and 19 patients (30%) in the
control group (P  .03). At 24 hours, 24 patients (44%) in the ultra-
sound group and 21 (40%) in the control group had dramatic clinical
recovery (P .7). At 3 months, 22 (42%) of 53 patients in the ultrasound
group and 14 (29%) of 49 patients in the control group were eligible for
follow-up analysis and had favorable outcomes (modified Rankin scale
score of 0 to 1, P  .20).
Comment: The study indicates enhancement of tPA therapy with
TCD ultrasonography in patients with acute ischemic stroke can be
achieved safely and may approve the efficacy of systemic therapy with tPA
in cases of acute ischemia stroke. The mechanism of ultrasound enhance-
ment of thombolysis is unclear and may be related to ultrasound-induced
cavitation effects on the thrombus resulting in increased permeability of
the thrombus to tPA. The study suggests a possible therapeutic role for
the vascular laboratory in the treatment of patients with acute ischemic
stroke.
Esterified estrogens and conjugated equine estrogens and the risk of
venous thrombosis
Smith ML, Heckbert SR, Lemaitre RN, et al. JAMA 2004;292:1581-7.
Conclusion: Equine-derived estrogens, but not esterified estrogens,
are associated with increased venous thromboembolic (VTE) risk in peri-
menopausal and postmenopausal women.
Summary: Clinical trials indicating increased VTE risk associated with
perimenopausal and postmenopausal estrogen supplementation have em-
ployed oral conjugated equine estrogens. The authors sought to determine
whether these findings also apply to other estrogen compounds. They
compared risk of VTE among users of conjugated equine estrogens, esteri-
fied estrogens, and nonestrogen users. This was a population-based, case–
control study conducted among patients of a large health maintenance
organization. The cases included perimenopausal and postmenopausal
women aged 30 to 89 years who had a first episode of VTE from January
1995 to December 2001. The controls were matched by age, hypertension
status, and calendar year. The main outcome measure was the risk of first
VTE with respect to use of esterified or conjugated equine estrogens with or
without progestin.
The authors identified 586 first-time VTE cases and 2,268 controls.
Current users of esterfied estrogen had no increase in VTE risk (odds ratio
[OR], 0.92; 95% confidence interval [CI], 0.69 to 1.22) compared with
controls. Women taking conjugated equine estrogen had an elevated risk
(OR, 1.65; 95% CI, 1.24 to 2.19). Users of conjugated equine estrogen had
a higher risk of VTE than users of esterified estrogen (OR, 1.78; 95% CI,
1.11 to 2.84). An increased daily dose of conjugated equine estrogen was
associated with increased risk (trend P  .02). Among users of conjugated
equine estrogen and esterified estrogen, use of progestin was associated with
an increased risk compared with use of estrogen alone (OR, 1.60; 95% CI,
1.13 to 2.26).
Comment: Just as all quarterbacks and surgeons are not equal, it also
appears that estrogens, when used in perimenopausal and postmenopausal
women, are also not all the same. This study has significant implications for
potential selection of perimenopausal and postmenopausal hormone therapy
and may modify the implications of the findings of increased VTE risk
associated with estrogen therapy in The Women’s Health Initiative Study.
(See abstract Estrogen Plus Progestin and Risk of Venous Thrombosis in this
month’s abstract section of the journal.)
Estrogen plus progestin and risk of venous thrombosis
Cushman M, Kuller LH, Prentice R, et al and The Women’s Health
Initiative Investigators. JAMA 2004;292:1573-80.
Conclusion: The risk of venous thrombosis is doubled in postmeno-
pausal women treated with hormone therapy consisting of equine-derived
estrogen plus progestin. Estrogen plus progestin increased the risk of venous
thrombosis associated with age, overweight or obesity, and factor V Leiden.
Summary: This study reports final data on the incidence of venous
thrombosis in The Women’s Health Initiative Estrogen Plus Progestin
clinical trial. It examines the association of hormone therapy with venous
thrombosis and other thromboembolic risk factors. This double-blind,
randomized controlled trial included 1,608 postmenopausal women with
intact uteruses between 50 and 79 years old. Enrollment was from 1993 to
1998 at 40United States centers. Patients were randomly assigned to receive
conjugated equine estrogen plus progestin or placebo. The main outcome
measures were venous thromboembolism (VTE), either deep vein throm-
bosis or pulmonary embolus.
Mean follow-up was 5.6 years. VTE occurred in 167 women receiving
therapy and in 76 patients on placebo (3.5 vs 1.7/1,000-person years,
respectively; hazard ratio (HR), 2.06; 95% confidence interval, 1.57 to 2.7).
Compared with women aged 50 to 59 years taking placebo, the risk
associated with hormone therapy increased with age with a HR of 4.28 for
women aged 60 to 69 years and a HR of 7.46 for women aged 70 to 79
years. Compared with women who were normal weight and taking placebo,
the risk associated with hormone therapy increased among overweight and
obese women, HR 3.80 and 5.61, respectively. Factor V Leiden also
enhanced the hormone-associated risk of VTE, with a 6.7-fold increased risk
compared with women in the placebo group without a factor V Leiden
deficiency. The generic variance of thrombosis risk did not modify the
association of hormone therapy with VTE.
Comment: This study has obvious immense implications for use of
equine-derived estrogen for hormone therapy in menopausal symptoms. It
appears all women undergoing postmenopausal hormone therapy with
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